Review article

Panax ginseng as an adjuvant treatment for Alzheimer’s disease

Hyeon-Joong Kim 1, Seok-Won Jung 1, Seog-Young Kim 2, Ik-Hyun Cho 2, Hyoung-Chun Kim 4, Hyewhon Rhim 3, Manho Kim 6, Seung-Yeol Nah 1,*

1 Ginsentology Research Laboratory and Department of Physiology, College of Veterinary Medicine, Konkuk University, Seoul, Republic of Korea
2 Department of Convergence Medicine, University of Ulsan College of Medicine and Institute of Life Science, Asan Medical Center, Seoul, Republic of Korea
3 Department of Convergence Medical Science, College of Korean Medicine, Kyung Hee University, Seoul, Republic of Korea
4 Neuropsychopharmacology and toxicology program, College of Pharmacy, Kangwon National University, Chuncheon, Republic of Korea
5 Center for Neuroscience, Korea Institute of Science and Technology, Seoul, Republic of Korea
6 Department of Neurology, Neuroscience Research Center, Seoul National University Hospital, Seoul, Republic of Korea

A R T I C L E  I N F O

Article history:
Received 28 November 2017
Received in Revised form 29 November 2017
Accepted 12 December 2017
Available online 12 January 2018

Keywords:
Adjuvant
Alzheimer’s disease
Ginsenoside
Gintonin
Panax ginseng

A B S T R A C T

Longevity in medicine can be defined as a long life without mental or physical deficits. This can be prevented by Alzheimer’s disease (AD). Current conventional AD treatments only alleviate the symptoms without reversing AD progression. Recent studies demonstrated that Panax ginseng extract improves AD symptoms in patients with AD, and the two main components of ginseng might contribute to AD amelioration. Ginsenosides show various AD-related neuroprotective effects. Gintonin is a newly identified ginseng constituent that contains lysophosphatidic acids and attenuates AD-related brain neuropathies. Ginsenosides decrease amyloid β-protein (Aβ) formation by inhibiting β- and γ-secretase activity or by activating the nonamyloidogenic pathway, inhibit acetylcholinesterase activity and Aβ-induced neurotoxicity, and decrease Aβ-induced production of reactive oxygen species and neuroinflammatory reactions. Oral administration of ginsenosides increases the expression levels of enzymes involved in acetylcholine synthesis in the brain and alleviates Aβ-induced cholinergic deficits in AD models. Similarly, gintonin inhibits Aβ-induced neurotoxicity and activates the nonamyloidogenic pathway to reduce Aβ formation and to increase acetylcholine and choline acetyltransferase expression in the brain through lysophosphatidic acid receptors. Oral administration of gintonin attenuates brain amyloid plaque deposits, boosting hippocampal cholinergic systems and neurogenesis, thereby ameliorating learning and memory impairments. It also improves cognitive functions in patients with AD. Ginsenosides and gintonin attenuate AD-related neuropathies through multiple routes. This review focuses research demonstrating that ginseng constituents could be a candidate as an adjuvant for AD treatment. However, clinical investigations including efficacy and tolerability analyses may be necessary for the clinical acceptance of ginseng components in combination with conventional AD drugs.

© 2018 The Korean Society of Ginseng. Published by Elsevier Korea LLC. This is an open access article under the CC BY-NC-ND license (http://creativecommons.org/licenses/by-nc-nd/4.0/).

1. Introduction

Alzheimer’s disease (AD) is a chronic neurodegenerative disease that primarily affects the elderly [1]. It usually occurs after 65 years; its incidence is approximately 10% in people aged ≥65 years, but the percentage of individuals with AD drastically increases with age [2]. AD is one of the most expensive diseases in the world because a therapeutic drug is not currently available. It is clinically characterized by learning and memory impairments, as well as deterioration of other cognitive and noncognitive mental functions [2]. The hallmark of patients with AD is the accumulation of amyloid plaques in the neocortical and limbic areas [3]. The gradual increase in
amyloid plaque deposits because of brain amyloidogenesis for more than several years induces neuronal cell death, resulting in brain atrophy and deficits. In particular, the loss of cerebral cortical and hippocampal neurons is linked to cognitive impairments and abnormal behaviors [4].

Because amyloid β-protein (Aβ) is neurotoxic and accumulates as amyloid plaques and tau tangles in the brains of patients with AD, Aβ and tau hyperphosphorylation is thought to be responsible for the disease [5]. Amyloid precursor protein (APP) is an integral membrane protein present in neuronal bodies and synapses. Aβ, containing 37–49 amino acid residues, is produced from APP via amyloidogenesis caused by two enzymes, β- and γ-secretase [6]. In addition to amyloid plaque deposits, another important feature of AD is cholinergic dysfunction, which occurs in several brain areas, such as the basal forebrain, cortical regions, and the hippocampus. The loss of cholinergic neurons in brains with cognitive deficits is closely associated with a decrease in acetylcholine levels due to the reduced activity of enzymes involved in acetylcholine synthesis [7,8]. In addition, several factors are postulated to cause AD, such as oxidative stress, neuroinflammation, mitochondrial dysfunction, glutamatergic excitotoxicity, and reduced levels of neurotrophic factors [9–12]. Deficient hippocampal neurogenesis is also seen in patients with AD [13]. Therefore, it appears that AD is a complex disease accompanied by several deleterious conditions in the brain: amyloid plaque deposits, malfunctions in the brain cholinergic system, oxidative stress, and brain inflammation accompanying diminished neurogenesis in the adult hippocampus [3,7].

Current Food and Drug Administration–approved treatments of AD are mainly based on two pharmacological modulations of cholinergic [i.e., acetylcholinesterase (AChE) inhibitors, which reduce acetylcholine] and glutamatergic (i.e., NMDA (n-methyl-d-aspartic acid) receptor antagonists, which reduce glutamate excitotoxicity) systems in the brain [14]. Although this can result in symptomatic improvement, it has been reported that the underlying progression of AD is unaffected by these therapies. In addition, long-term treatments can cause various adverse effects [15–17]. Besides the two conventional pharmacologic interventions, there are reports of additional strategies for AD treatment, such as the use of antiinflammatory drugs, lowering of blood pressure, and hormone replacement therapy. In addition, herbal therapy using herbal medicines such as Panax ginseng has received attention as an alternative and complementary intervention for neurodegenerative diseases, especially AD [18–21].

Ginseng (Panax ginseng Meyer) root has been widely used in the far eastern countries such as China, Japan, and Korea for thousands of years as a traditional tonic for longevity. In traditional medicine, ginseng was simply decocted with water and prepared as a drink (Fig. 1A). The tonic effects of ginseng extract include energizing the body or increasing vital energy, mood elevation, and longevity. Ginseng extract has been previously considered as a nonspecific agent for increasing resistance against various diseases and stresses as an adaptogen, when its mode of action is unknown [22].

Fig. 1. A brief description of the methods used in ginseng extract preparation from the past to the present. The isolation of the active constituents of ginseng or the isolation or fractionation of the portion containing the active components (C) is required for the production of a nutraceutical or natural medicine instead of using a simple water ginseng extract (A) or a whole ginseng concentrate (B) after water and/or alcohol extraction.
Currently, ginseng is used as a functional food or alternative and/or a complementary medicine worldwide. Ginseng-containing commercial products are prepared by extraction with water and/or alcohol to obtain water-soluble and/or water-insoluble components from ginseng, respectively (Fig. 2B). One of the main merits of ginseng extract is that it exhibits a variety of effects with fewer side effects than those exhibited by other herbal medicines.

Ginsenosides (also called ginseng saponins) are the first active ingredients isolated from ginseng (Fig. 2A). They are a type of triterpenoid dammarane glycosides. The common characteristic of ginsenosides is a hydrophobic, four-ring, steroid-like backbone and carbohydrate moieties at the carbon-3, carbon-6, or carbon-20 positions [23,24]. Approximately 30 ginsenosides have been identified from ginseng, using current ginseng-processing methods. Ginsenosides are classified as protopanaxadiol (e.g., ginsenoside Rb1) or protopanaxatriol (e.g., ginsenoside Rg1). Ginseng and ginsenosides exhibit a variety of beneficial pharmacological effects outside of the nervous systems, such as anticancer, antiinflammation, antioxidant, and vasorelaxative effects [25–28]. In the nervous system, recent studies have demonstrated that ginsenosides exhibit a variety of pharmacologically beneficial effects in vitro and in vivo in animal models related to neurodegenerative diseases such as AD [29–31].

Recent studies have shown that ginseng also contains a novel ginseng-derived G protein–coupled lysophosphatidic acid (LPA, 1-acyl-2-hydroxy-sn-glycero-3-phosphate) receptor ligand, gintonin (Fig. 2B) [32]. Gintonin is distinct from previously identified ginseng saponins and other ginseng components in that it consists of carbohydrates, lipids, and ginseng proteins in a glycolipoprotein complex [32]. The representative functionally active components of gintonin are the LPAs and other lipids [33]. Gintonin LPAs consist of LPA C16:0, LPA C18:1, and LPA C18:2 (Fig. 2B). The order of LPA species in gintonin from most to least abundant is LPA C18:2 >>> LPA C16:0 > LPA C18:1. Interestingly, ginseng contains an extraordinarily high number of LPAs, 10-fold greater than other herbal medicines and foodstuffs [34]. The characteristics of gintonin LPAs enable selective activation of LPA receptors with high affinity [33]. Gintonin LPAs are isolated in a complex with ginseng proteins called ginseng major latex-like protein 151 (GLP151) [35] (Fig. 3). The complex of LPAs and ginseng proteins may provide at least two advantages to the physiological and pharmacological actions of LPAs. First, free forms of LPAs are susceptible to the action of LPA hydrolisis enzymes, such as lipid phosphatase [36], whereas gintonin LPAs are more soluble and stable [34]. Second, it appears as if GLP151 acts as a carrier and/or transporter for the delivery of LPA to their respective LPA receptors [35,37] (Fig. 3). Gintonin exerts its physiological and pharmacological actions in the nervous system through the LPA receptor-Gαq/11 protein-phospholipase C-IP3 receptor-[Ca\\(^{2+}\)] transient pathway [33], which is also associated with in vitro and in vivo anti-AD activity in the nervous system [35].

This review first introduces that ginseng extract exhibits symptomatically improving effects in patients with AD rather than other neurodegenerative diseases, when it combines with conventional AD drugs, although it is not a disease-modifying drug. This review then shows the extensive studies that ginsenosides and gintonin, refined components derived from Panax ginseng extract, exhibit in vitro and in vivo anti-AD benefits and finally proposes the idea that both components can be used as an adjuvant for the enhancement of conventional AD treatments.

2. Effects of ginseng extract on animal models of and patients with AD

2.1. Effects of ginseng extract on in vitro and in vivo animal AD model

Recent studies on the efficacy of Panax ginseng extract against aging-related brain diseases, such as AD, have shown that ginseng extract inhibits Aβ-induced neurototoxicity in vitro and attenuates Aβ accumulation in the brain in vivo animal studies [38]. Administration of fermented ginseng extract in a mouse model of AD improved memory function and reduced Aβ formation in the brain [39]. White, red, and black ginseng extract also attenuated hippocampal Aβ oligomer injection–induced memory dysfunction in mice through AChE inhibition [40]. Oral administration of white ginseng extract to Aβ oligomer–injected mice restored the reduced synaptophysin and choline acetyltransferase activity [41].

Fig. 2. The two main active ingredients of ginseng that produce anti-Alzheimer’s effects. (A) Ginsenosides consist of a triterpenoid dammarane backbone with carbohydrates attached at different positions. (B) The chemical structures of lysophosphatidic acids (LPAs) isolated from ginseng gintonin.
2.2. Effects of ginseng extract on dementia patients with AD

A number of studies have shown that the long-term administration of Korean Red Ginseng extract to patients with AD, combined with conventional AD drugs, gradually improved cognitive function, as assessed using the mini-mental state examination (MMSE) and Alzheimer’s Disease Assessment Scale—Cognitive Subscale (ADAS-Cog) tests, with minor adverse effects [42–44]. MMSE test informs us the degree of cognitive impairment including attention, recall, registration, language, ability to follow simple commands, and orientation [36]. ADAS-Cog test gives us on the disturbances of memory, language, praxis, attention, and other cognitive abilities as the core symptoms of AD [45]. Long-term treatment with relatively high amounts of Korean Red Ginseng extract for more than 12 weeks also improved the frontal assessment battery, which is an indication of frontal cortical activity, such as right temporal, parietal, and occipital areas, in elderly patients with AD [45]. These reports show that various ginseng extracts, such as white ginseng, fermented ginseng, and red ginseng, could result in the alleviation of AD symptoms, to some extent, in animal models and patients. This indicates that ginseng extracts contain certain biologically active components that may prevent cognitive dysfunction due to a reduced Aβ burden and amyloid plaque accumulation.

Furthermore, recent reports have provided information that ginseng components, such as ginsenosides and gintonin, may be responsible for ginseng extract–mediated anti-AD activity via the inhibition of Aβ-induced neurotoxicity and reactive oxidation stress; stimulation of soluble amyloid precursor protein α (sAPPα) formation (but not Aβ); antiinflammatory effects; and boosting cholinergic systems, hippocampal neurogenesis, and cognitive functions. The subsequent sections will review the accumulated in vitro and in vivo evidence indicating that ginsenosides and gintonin are responsible for the anti-AD effects of ginseng extract.

3. Effects of ginseng components on Aβ formation

3.1. Inhibition of Aβ formation by ginsenosides

Integral membrane APP processes in the brain involve two pathways, one for the production of neurotoxic Aβ, and one for the production of beneficial sAPPα. Brain amyloidogenesis is initiated by β- and γ-secretase and results in the production of diverse forms of Aβ [6]. These Aβs are not soluble and spontaneously aggregate and accumulate in the brain to form amyloid plaques, which damage nearby neurons [6]. Over time, the number of neurons diminishes with an increase in amyloid plaque deposits. As a result, brain function, including cognition, declines. On the contrary, activation of α-secretase cleaves the middle portion of the Aβ peptide after γ-secretase action to produce sAPPα; this is the nonamyloidogenic pathway and is beneficial to neurons [46]. sAPPα has been shown to exhibit protective and proliferative properties in a variety of cell types, such as neural progenitor cells in the subventricular zone of adult mice, fibroblasts, thyroid epithelial cells, and embryonic stem cells [46]. Therefore, the inhibition of β- and γ-secretase, which enables suppression of the amyloidogenic pathway, may be a potential target for anti-AD drug development. The stimulation of the nonamyloidogenic pathway through the activation of α-secretase may be an alternative way to reduce the formation of Aβ in the brain.

Accumulating evidence shows that ginsenosides negatively regulate β-secretase activity. In in vitro enzyme assays, ginsenosides Rb1, Rb2, and Rc inhibited β-secretase activity. In molecular docking studies, ginsenosides Rb1 and Rb2 exhibited high binding affinities for β-secretase. Karpagam et al (2013) also demonstrated that ginsenosides CK, F1, Rh1, and Rh2 can act as potential β-secretase inhibitors when evaluating their interactions with β-secretase [47,48]. At the cellular level, ginsenoside Rd increased sAPPα expression level that was reduced by inhibition of the mitogen-activated protein kinase (MAPK) and phosphoinositide-3 kinase (PI3K) pathways in HT22 hippocampal neuronal cells. In addition, one study showed that ginsenoside Rd stimulated sAPPα release via estrogen receptors. In ovariectomized rats, intraperitoneal administration of ginsenoside Rd increased the levels of sAPPα, reduced extracellular Aβ, and alleviated cognitive and memory impairments. Furthermore, ginsenoside Rd–mediated amelioration of AD-related dysfunction and activation of the MAPK and PI3K pathways was blocked by an estrogen receptor antagonist [49]. These results suggest that ginsenoside Rd likely acts through estrogen receptors to enhance learning and memory function and activation of the nonamyloidogenic pathway for stimulation of sAPPα formation. Ginsenoside Re decreased Aβ levels in N2a/APP695 cells. A study of the molecular mechanisms showed that ginsenoside Re decreased the levels of both β-secretase mRNA and protein and inhibited β-secretase activity in N2a/APP695 cells. Ginsenoside Re–mediated reductions of β-secretase mRNA and
protein were achieved via an increase of peroxisome proliferator—activated receptor-γ (PPARγ) expression. Ginsenoside Re also stimulated PPARγ activity. Therefore, ginsenoside Re—mediated inhibition of β-secretase activity is achieved via activation of PPARγ, which ultimately reduces the generation of Ab40 and Ab42 [50].

In addition to the effects of ginsenosides on β-secretase activity, ginsenoside Rg1 treatment inhibited the activity of γ-secretase in both B103-APP cells and Tg mAPP mouse brain tissues, indicating that ginsenoside Rg1 is also involved in the APP regulation pathway. The underlying mechanisms of ginsenoside Rg1—induced inhibition of γ-secretase activity involve the enhancement of protein kinase A/CREB (cAMP response element—binding protein) pathway activation in Tg mAPP mice [51]. On the other hand, in in vitro studies using HT22 cells and SH-SY5Y cells stably expressing the Swedish mutant APP, ginsenoside Rg1 also increased extracellular secretion of sAPPα, enhanced γ-secretase activity, and decreased extracellular release of Ab. Ginsenoside Rg1—induced increase of sAPPα was blocked by inhibitors of protein kinase C, extracellular-signal—regulated kinase, and the MAPK and PI3K/Akt pathways [52,53]. Therefore, ginsenoside Rg1 may utilize signaling enzymes for sAPPα instead of its production per se through the activation of γ-secretase and inhibition of β- and γ-secretase. Ginsenoside Rh2 increased sAPPα levels, increased CTFα/β (C-terminal fragments of APPα/β) ratios, and reduced Ab40 and Ab42 levels in primary hippocampal neurons. Furthermore, ginsenoside Rh2 increased surface APP levels drastically. In addition, ginsenoside Rh2 inhibited APP endocytosis by reducing cholesterol and lipid raft concentrations [54]. In in vivo studies, long-term intraperitoneal administration of ginsenoside Rh2 to a Tg2576 mouse model of AD significantly improved learning and memory performance and reduced the size of senile plaques at 14 months. On the other hand, there are a few reports indicating that ginsenoside affects Ab-related tau hyperphosphorylation in the brain, which is also thought to contribute to AD. Treatment of cortical neurons with Ab increased tau hyperphosphorylation by increasing GSK-3β (glycogen synthase kinase-3β) expression. However, pretreatment with ginsenoside Rb1 attenuated Ab25-35-induced tau protein hyperphosphorylation by inhibiting the expression of GSK-3β [55]. Indirect regulation of tau hyperphosphorylation by ginsenoside Rd has also been reported. Ginsenoside Rd inhibits the tau protein hyperphosphorylation that was increased by okadaic acid, a protein phosphatase inhibitor, in cultured cortical neurons [56] (Fig. 4). Recently, isolated ginseng protein also exhibited anti-AD activity. Ginseng protein improved the memory ability and reduced the amount of Ab1-42 and p-tau in an AD rat model. The anti-AD effects of ginseng protein appear to be mediated by PI3K/Akt signaling pathway activation [57], raising the possibility that ginseng protein and ginsenosides may also have anti-AD activity.

3.2. Inhibition of Aβ formation by gintonin

It has recently been reported that gintonin facilitates sAPPα production through the LPA receptor-Gαq/11-phospholipase C-IP3 receptor-[Ca2+]i transient pathway [33]. Application of gintonin to SH-SYSY neuroblastoma cells stimulated sAPPα release in a [Ca2+]i transient-dependent manner via the LPA receptor signaling mechanisms.
pathway and α-secretase activation. In addition, application of gintonin to SH-SY5Y neuroblastoma cells decreased Aβ formation and attenuated Aβ-induced neurotoxicity, indicating that gintonin could affect APP processing in the brain [58]. In another study using a mouse model of AD, long-term oral gintonin treatment decreased amyloid plaque deposits in the cortex and hippocampus [58]. In addition, long-term gintonin treatment in an AD mouse model ameliorated cognitive deficits in various behavioral tests related to spatial and associative memory [58]. Therefore, gintonin-mediated activation of the in vitro non amyloidogenic pathway via LPA receptor signaling pathways is further linked to the in vivo attenuation of brain AD-related neuropathies (Fig. 5).

4. Effects of ginseng components on the brain's cholinergic systems

4.1. Effects of ginsenosides on the brain's cholinergic systems

Brain acetylcholine levels are decreased in AD mouse models and in patients with AD due to a decrease in the acetylcholine synthesis enzyme, choline acetyltransferase (ChAT), and an increase in the acetylcholine degradation enzyme, AChE [7,8]. Because acetylcholine plays an important role in cognitive functions, an imbalance in acetylcholine levels may cause cognitive deficits, for example, in learning and memory, in AD animal models and patients with AD. In addition, ginsenosides, such as ginsenosides Rd and Re (but not Rb1, Rg1, and Rg3), are involved in in vitro and in vivo acetylcholine metabolism in neuronal cells. Ginsenosides Rd and Re induce an increase in acetylcholine synthesis in neuro-2a cells [59]. Ginsenosides Rd and Re upregulate the expression of ChAT, resulting in an increase in the levels of acetylcholine and vesicular acetylcholine transporter, both of which are required for cholinergic neurotransmission. In addition, these ginsenosides increased the expression of microtubule-associated protein-2, nerve growth factor receptor (p75), p21, and TrkA (tropomyosin receptor kinase A), indicating that ginsenoside Rd and Re affect neuronal differentiation and the nerve growth factor—TrkA signaling pathway, in addition to the cholinergic system. Orally administered ginsenoside Re and Rd increased the expression levels of ChAT and vesicular acetylcholine transporter mRNA in the brain [59]. A ginsenoside Rb1—enriched preparation, Cereboost, attenuated Aβ1-42-induced cytotoxicity in F3.ChAT stem cells and increased ChAT gene expression. Oral administration of Cereboost reversed Aβ1-42—induced cognitive dysfunction and increased levels of microtubule-associated protein-2 and synaptophysin in the brain, as well as the acetylcholine concentration [60] (Fig. 4).

4.2. Effects of gintonin on cholinergic systems in the brain

Gintonin-mediated LPA receptor activation has been shown to increase the release of acetylcholine in hippocampal progenitor cells and choline acetyltransferase expression levels, indicating that gintonin may induce the differentiation of hippocampal neural progenitor cells into cholinergic neurons [61]. In addition, in an in vivo study, oral administration of gintonin for 3 weeks also increased hippocampal ChAT expression levels in wild-type mice. Long-term administration of gintonin in a mouse model of AD
increased acetylcholine levels in the hippocampus. Gintonin also increased ChAT expression levels and reduced AChE expression in the hippocampus [61]. Therefore, gintonin exerts its effects on the cholinergic system in at least two ways: the induction of in vitro differentiation of hippocampal neural progenitor cells into cholinergic cells by increasing the level of ChAT expression and by in vivo restoration of the hippocampal cholinergic system through the elevation of acetylcholine levels via an increase in ChAT and a decrease in AChE (Fig. 5).

5. Effects of ginseng components on Aβ-induced reactive oxidative stress

5.1. Effects of ginsenosides on Aβ-induced reactive oxidative stress

It is well known that Aβ induces oxidative stress in neuronal cells, resulting in cell death [11]. Accumulating evidence shows that ginsenosides exhibit in vitro neuroprotective effects against neuronal cell apoptosis caused by Aβs such as Aβ1-42, Aβ1-40, and Aβ1-38. The mechanisms of the neuroprotective effects of ginsenosides against Aβ neurotoxicity are closely related to its attenuation of reactive oxidative stress. For example, exposure of PC12 cells, cortical neurons, or hippocampal cell cultures to Aβ1-42 led to the accumulation of reactive oxygen species (ROS) and lipid peroxidation, increases of malondialdehyde (MDA) products, and decrease of superoxide dismutase (SOD) activity, respectively, and eventually causing a decrease in cell survival [52,62,63]. Pretreatment with ginsenoside Rb1 or Rg1 not only inhibited Aβ-induced ROS overproduction and lipid peroxidation but also decreased lactate dehydrogenase release, MDA production, and SOD activity, thereby improving the rate of cell survival. Ginsenosides Rb1 and Rg1 may serve as potent scavengers of ROS produced by Aβs [52,62,63]. Another study on ginsenoside Rd antioxidant effects on Aβ25-35-induced neurotoxicity showed that ginsenoside Rd significantly ameliorated Aβ25-35-induced oxidative stress by decreasing ROS production and MDA levels and increasing the levels of SOD and glutathione peroxidase, comparable with other antioxidants, such as probucol and edaravone [64]. Ginsenosides such as ginsenosides Rb1, Rd1, or Rg1 may exert their anti-AD effects through the reduction of oxidative stress and attenuation of reactive oxidative stress—induced neuronal apoptosis. On the other hand, it is known that Aβs induce mitochondrial dysfunction by decreasing the mitochondrial membrane potential and ATP (adenosine triphosphate) levels and inhibiting cytochrome c activity in neurons. However, ginsenoside Rg1 treatment reversed Aβ1-42-induced mitochondrial dysfunction and the death of cortical neurons. The protective effects of ginsenoside Rg1 against the mitochondrial dysfunction induced by Aβ is achieved through the suppression of intracellular mitochondrial oxidative stress [65]. Therefore, these reports show that the innate antioxidative properties of ginsenosides can be used for the reduction of Aβ-induced oxidative stress (Fig. 4).

6. Effects of ginseng components on Aβ-induced neuroinflammation

6.1. Effects of ginsenosides on Aβ-induced neuroinflammation

Microglia are known as the major inflammatory response cells of the central nervous system [66]. Aβ, in addition to being a reactive oxidative stress inducer, is an inducer of microglial activation and neuroinflammation. It is known that Aβ-induced neuroinflammation via microglial activation is an event associated with the onset and progression of the neuropathophysiology of AD [67]. In addition to ginsenoside-induced antioxidative stress, there are several reports on the attenuation of neuroinflammation by ginsenosides. Ginsenoside Rb1 treatment significantly attenuated neuroinflammation markers, such as cyclooxygenase-2, that were induced by Aβ1-42 [68]. Li et al (2011) showed that ginsenoside Rg1 exhibited anti-inflammatory effects by inhibiting neurotoxic interleukin (IL)-1β, IL-8, and tumor necrosis factor-α production in THP1 monocytes stimulated by Aβ1-40 and prevented neuronal cell apoptosis [56]. These results indicate that a direct modulation of immune cells by ginsenoside Rg1 is coupled to its anti-AD activity via attenuation of the Aβ1-40-induced inflammation of immune cells. Ginsenoside Rg3 enhances microglial phagocytosis of Aβ and promotes Aβ uptake, internalization, and digestion. Increased maximal Aβ uptake was observed at 4 h and 8 h after pretreatment with ginsenoside Rg3, and the internalized Aβ was almost completely digested from the cells within 36 h [69]. In addition, the expression of type A macrophage scavenger receptors was also upregulated by ginsenoside Rg3 treatment in the cytosol. Ginsenoside Rg3 stimulation of the type A macrophage scavenger receptor may contribute to its therapeutic potential for AD via microglial phagocytosis and digestion [69]. Therefore, ginsenosides may achieve their anti-AD effects by attenuating Aβ-mediated neuroinflammation and facilitating microglial phagocytosis (Fig. 4).

6.2. Effects of gintonin on Aβ- and inflammatory agent—induced inflammation

There are only a few reports of the inhibitory effects of gintonin on Aβ- and inflammatory agent—induced inflammation. In vivo long-term administration of gintonin in an AD mouse model attenuated the expression level of allograft inflammatory factor-1, a marker for microglia activation, in the cortex and hippocampus, indicating that gintonin exhibits anti-inflammatory effects by inhibiting the inhibition of microglial activation and by enhancing microglial phagocytosis [58]. In one in vitro study, gintonin applied to RAW 264.7 cells inhibited the lipopolysaccharide-induced production of proinflammatory cytokines such as IL-6, IL-1β, and tumor necrosis factor-α via the MAPK and nuclear factor-kappa B pathways. Gintonin also restored the levels of miR-34a and miR-93 that were downregulated by lipopolysaccharide treatment [70]. In addition, oral administration of a gintonin-enriched fraction inhibited the increase in expression of inflammatory mediators (e.g., IL-1β, tumor necrosis factor-α, IL-8, and tumor necrosis factor-α) in serum caused by an inflammatory agent, 2,4-dinitrofluorobenzene [71]. Gintonin has also been shown to exhibit anti-inflammatory effects in the brain and periphery.

7. Effects of ginseng components on hippocampal neurogenesis

7.1. Effects of gintonin on hippocampal neurogenesis

A recent study showed that a mouse model of AD and patients with AD exhibit increased neurogenesis in the hippocampus [72], indicating the possibility that the brain itself compensates for or protects against Aβ insults. Neurogenesis in the brain, especially hippocampal neurogenesis in the adult brain, is a target for anti-AD treatments [72]. In fact, several studies have shown that various factors affect hippocampal neurogenesis, such as inflammation inhibition, enriched environments, physical exercise, reduction of stress, and the supply of neurotrophic factors such as brain-derived neurotrophic factor and epidermal growth factor [14]. In addition, several medicinal plants, including ginseng extract, promote hippocampal neurogenesis without a definite mechanism of action [73,74]. Gintonin also stimulates in vitro hippocampal neural progenitor proliferation through the LPA receptor signaling pathways.
Previous reports have shown that LPA1 receptor–deficient mice exhibit reduced hippocampal cell proliferation [75]. Interestingly, treating hippocampal neural progenitor cells with gintonin also induced cells to differentiate into neurons and astrocytes [76]. Gintonin also increased the expression of the LPA1 receptor in hippocampal neural progenitor cells, indicating that gintonin-mediated differentiation and proliferation of hippocampal neural progenitor cells is closely related to hippocampal LPA receptors [76]. Oral administration of gintonin to wild-type mice stimulated cell proliferation in the CA1 (cornu ammonis 1), CA3, and dentate gyrus areas of the hippocampus. Long-term treatment of AD mice with gintonin also increased hippocampal neurogenesis by increasing LPA1 receptor expression [76]. In addition to gintonin-mediated activation of the nonamyloidogenic pathway and restoration of the hippocampal cholinergic system, gintonin-mediated hippocampal neurogenesis may be another target for anti-AD therapy [58,61,75] (Fig. 5).

8. Gintonin improves impaired cognitive functions in elderly AD dementia

Moon et al (2017) further investigated the proof-of-concept effect of gintonin in patients with AD with combination of conventional AD drugs [78]. In parallel to preclinical tests [58,61,75], gintonin administration displayed potential cognition-enhancing effects in cognitively impaired subjects, when compared with those before gintonin administration in two tests, such as MMSE and ADAS-Cog [79]. Administration of gintonin for 4 weeks improved the score of MMSE test significantly on the first and second follow-up visits compared with the baseline. Administration of gintonin for 4 weeks also decreased ADAS-Cog score significantly at the first follow-up visit and continued to decrease at subsequent visits. ADAS-nonCog scores were significantly improved 4 weeks after the daily consumption of gintonin with conventional AD drug treatments [78]. Interestingly, the previous administration of a large amount of whole ginseng extract induced adverse effects such as facial flushing, headache, dizziness, and gastrointestinal disorders [42,44], whereas gintonin administration did not induce any adverse effects in elderly AD dementia throughout whole investigations [78]. Although this study has a limitation with small sample size and further needs large-scale clinical studies, this study suggests that gintonin is safe as a ginseng component and can be an effective way to improve cognition in dementia patients with combination of conventional AD drugs.

9. Perspective and conclusion

Panax ginseng has been used to promote longevity since the ancient Ch’in dynasty in China. The whole ginseng plant was traditionally decocted, and an extract or concentrate was used as a functional food or an herbal medicine for diverse purposes (Fig. 1A and B). Recent reports have shown that ginseng extracts prepared using diverse processing methods, such as white ginseng, red ginseng, black ginseng, and fermented ginseng, improve AD-related cognitive dysfunctions in patients with AD [42,43,45]. Therefore, accumulating experimental evidence suggests that ginseng extract has anti-AD effects. But treatment with ginseng extract may have certain limitations [42,43,45] because ginseng extract that contains various unidentified ginseng components could not explain exact mode of action on the improvements of AD symptoms.

Two active components of ginseng, ginsenosides and gintonin, may underlie the anti-AD benefits shown by ginseng extract. The molecular basis of the two ginseng components that mediate anti-AD activity in vitro or in vivo AD mouse models may include five different mechanisms. These mechanisms include the stimulation of nonamyloidogenic ß-secretase activity via the LPA receptor signaling pathway and inhibition of ß- and ð-secretase activity, restoration of the hippocampal cholinergic system, attenuation of mitochondrial oxidative stress and neuroinflammation, and enhancement of hippocampal neurotrophic factor expression, and neurogenesis (Table 1). Therefore, ginsenosides and/or gintonin exert their anti-AD activities via multiple target actions in the brain rather than by the single target approach used in conventional AD treatments. Isolated or fractionated ginsenosides or gintonin could be prepared as an adjuvant therapy for the amelioration of AD through multiple targets (Fig. 1C).

### Table 1
Summary of anti-Alzheimer’s disease effects of Panax ginseng extract and its components

| Alzheimer’s disease–related neuropathies | In vitro or in vivo treatments | References |
|----------------------------------------|-------------------------------|------------|
| **β-Amyloids**                         |                               |            |
| Amyloidogenic pathways                 | β-secretase activity ↓        | [47,51]    |
|                                       | γ-secretase activity ↓        |            |
| Non-amyloidogenic pathway and sAPPα formation | β-secretase activity ↓        | [46,49,58] |
|                                       | γ-secretase activity ↓        |            |
| Aβ formation                          | inhibition                    | [52,53,58] |
| Aβ-induced toxicity in neuronal cells  | Inhibition                    | [41,58,65] |
| In vivo brain amyloid plaque formations | Inhibition                    | [38,54,58] |
| Tau hyperphosphorylation               | ND                           | [55]       |
| **Brain cholinergic system**           |                               |            |
| Choline acetyltransferase activity and expression | Stimulation                  | [59,60,61] |
| Acetylcholinesterase activity and expression | Inhibition                   | [59,60,61] |
| In vitro and in vivo brain acetylcholine level | Increase                    | [59,60,61] |
| Aβ-induced oxidative stresses         |                               |            |
| Formations of free radicals            | Inhibition                    | [62,63]    |
| Aβ-induced neuroinflammation          | Inhibition                    | [56,58,68] |
| Inflammation-related products (COX-2, IL-1), IL-8 and TNF-α, or Iba-1 and microglial activations | Inhibition |            |
| Hippocampal neurogenesis               | ND                           | [75,77]    |
| Plasma target protein for Alzheimer’s disease | ND                           | LPA receptors [75] |
| Applications to AD patients            |                               |            |
| Cognitive function in ADAS and MMSE tests | Improvement                  | [42,43,44,45,78] |

| Aβ, β-amyloid; AD, Alzheimer’s disease; ADAS, Assessment Scale—Cognitive Subscale; COX-2, cyclooxygenase-2; Iba-1, allograft inflammatory factor-1; IL-1β, interleukin-1β; IL-8, interleukin-8; MMSE, mini-mental state examination; ND, not determined; sAPPα, soluble amyloid precursor protein α; TNF-α, tumor necrosis factor-α. |
Some of the anti-AD benefits of ginsenoside overlap with those of gintonin. For example, protection against Aβ-induced neurotoxicity and inhibition of Aβ formation have been found for both ginsenosides and gintonin. In addition, both ginsenosides and gintonin also reinforce the brain cholinergic systems. Therefore, indirect ginsenoside- and gintonin-mediated boosting effects on the cholinergic system may prove to be more advantageous than those of direct cholinergic receptor agonists because direct treatment with cholinergic receptor agonists can produce gastrointestinal side effects in humans because of the high level of endogenous muscarinic cholinergic receptors in the gastrointestinal system [80]. However, ginsenoside-mediated attenuation of oxidative stress was not observed with gintonin, whereas gintonin-mediated increases of hippocampal neurogenesis and cognition-enhancing effects in cognitively impaired patients with AD were not observed with ginsenosides [78]. Therefore, ginsenosides and gintonin may complement each other, to some extent. Although some of the ginsenosides have diverse cytosolic kinase signaling pathways [48–50,52,53] (Fig. 4), the concrete molecular mechanisms of the various ginsenosides cannot be easily explained at the membrane level (Fig. 4). This may be because ginsenoside binding proteins at the cell membrane level are unknown or do not exist (Table 1). In contrast, gintonin-mediated anti-AD activity can be clearly explained because gintonin uses LPA receptor signaling pathways (Fig. 5 and Table 1) [37].

Several clinical trials run by large pharmaceutical companies that have targeted the inhibition of only Aβ formation or antibody therapy against Aβ for AD treatment have failed. In addition, conventional drugs such as AChE inhibitors and NMDA receptor antagonists currently used by physicians in AD clinics do not demonstrate sufficient therapeutic efficacy against AD with adverse effects. Because AD is a complex multifactorial disease involving multiple aspects of the brain, the multiple actions of ginsenosides and/or gintonin may prove more beneficial if they are combined with conventional single target drugs, such as AChE inhibitors or NMDA receptor antagonists [21]. The combination treatment of ginseng components, which shows multiple modes of actions, with conventional AD drugs which are single target drugs may provide advantages over monotherapy for the effective pharmacological management of AD [81,82]. Combination therapy with ginseng components as an adjuvant may enhance efficacy by inducing additive or synergistic effects. The combination of ginseng components with an AD drug might also improve safety and tolerability potentially with less side effects, making additional neuroprotective effects by prolonging the symptomatic benefits and ultimately delaying disease progression, although the combination therapy with ginseng components were not clinically demonstrated.

In conclusion, although administration of ginseng extract alone did not show enough monotherapeutic effects on AD progression, it can ameliorate cognition deficits in patients when combined with conventional AD drugs. Accumulating evidence has shown that two ginseng components, ginsenosides and gintonin, may be responsible for ginseng extract—mediated AD improvements through diverse molecular mechanisms in mouse models of AD. In the future, clinical investigations might be required for the mass assessment of the efficacy, safety, and tolerability when combining two ginseng components with conventional drugs to enhance AD treatment.

Conflicts of interest
The authors declare that the research was conducted in the absence of any commercial or financial relationships that could be construed as potential conflicts of interest.

Acknowledgments
This research was supported by Konkuk University in 2017.

References
[1] Burns A, Iliffe S. Alzheimer’s disease. BMJ 2009;338:b158.
[2] Querfurth HW, LaFerla FM. Alzheimer’s disease. N Engl J Med 2010;362:329–44. https://doi.org/10.1056/NEJMra0909412.
[3] Hardy J, Allsop D. Amyloid deposition as the central event in the aetiology of Alzheimer’s disease. Trends Pharmacol Sci 1991;12:383–8.
[4] Hollands C, Bartolotti N, Lazarov O. Alzheimer’s disease and hippocampal and nigrostriatal degeneration: sharing mechanisms. Front Neurosci 2010;4:178. https://doi.org/10.3389/fnins.2010.00178.
[5] Mudher A, Lovestone S. Alzheimer’s disease—do taus and baptists finally shake hands? Trends Neurosci 2002;25:22–6.
[6] Hooper MM. Roles of proteinosis and lipid rafts in the processing of the amylorid precursor protein and prion protein. Biochem Soc Trans 2005;33:335–8. https://doi.org/10.1042/BST0330335.
[7] Francis PT, Palmer AM, Snape M, Wilcock GK. The cholinergic hypothesis of Alzheimer’s disease: a review of progress. J Neurol Neurosurg Psychiatry 1999;66:137–47.
[8] Martorana A, Esposito K, Goch G. Beyond the cholinergic hypothesis: do current drugs work in Alzheimer’s disease? CNS Neurosci Ther 2010;16:235–45. https://doi.org/10.1111/j.1755-5949.2010.00175.x.
[9] Bagyinszky E, Giau VV, Shim K, Suk K, An SSA, Kim S. Role of inflammatory molecules in the Alzheimer’s disease progression and diagnosis. J Neurol Sci 2017;370:242–54. https://doi.org/10.1016/j.jns.2017.03.031.
[10] Hrosdov J, Singh N, Fisar Z. Mitochondrial dysfunctions in neurodegenerative diseases: relevance to Alzheimer’s disease. Biomed Res Int 2014;2014:1–9. https://doi.org/10.1155/2014/175062.
[11] Manoharan S, Guillemin GJ, Abramiansdori RS, Essa MM, Akbar M, Akbar MD. The role of reactive oxygen species in the pathogenesis of Alzheimer’s disease. Parkinson’s disease, and Huntington’s disease: a mini review. Oxd Med Cell Longev 2016;2016;8590758. https://doi.org/10.1155/2016/8590758.
[12] Zádori D, Veres G, Szalárdy I, Khvényi P, Toldy J, Vécsei L. Glutamatergic dysfunction in Alzheimer’s disease and related therapeutic targets. J Alzheimers Dis 2014;42(Suppl.3):S177–87. https://doi.org/10.3233/JAD-132621.
[13] Lazarov O, Hollands C. Hippocampal neurogenesis: learning to remember. Prog Neurobiol 2016;138:130–41. https://doi.org/10.1016/j.pneurobio.2015.12.006.
[14] Uzun S, Kozumplik O, Folenowicz-Smalec V. Alzheimer’s dementia: current data review. Coll Antropol 2011;35:1333–7.
[15] Creeley CE, Wozniak DF, Nardi A, Fabner NB, Olney JW. Donpezel marked potentiates memantine neurotoxicity in the adult rat brain. Neurobiol Aging 2008;29:153–67. https://doi.org/10.1016/j.neurobiolaging.2006.02.100.
[16] Högel HM. Brain food for Alzheimer-free ageing: focus on herbal medicines. Adv Exp Med Biol 2015;863:193–204. https://doi.org/10.1007/978-3-319-18367-5_5.
[17] Pangalos MN, Schechter LE, Hurko O. Drug development for CNS disorders: strategies for balancing risk and reducing attrition. Nat Rev Drug Discov 2006;5:621–12. https://doi.org/10.1038/nrd1903.
[18] Tian J, Shi J, Zhang X, Wang Y. Herbal therapy: a new pathway for the management of Alzheimer’s disease: a systematic review and meta-analysis of randomized controlled trials. Curr Top Med Chem 2016;16(5):529–36.
[19] Wang Y, Lu JG, Li H, Yang HM. Pharmacological effects of active components of Chinese herbal medicine in the treatment of Alzheimer’s disease: a review. Am J Chin Med 2016;44(8):1525–41.
[20] Yang WT, Zheng XW, Chen S, Shan CS, Xu QQ, Zhu JZ, Bao XY, Lin Y, Zheng GQ, Wang Y. Chinese herbal medicine for Alzheimer’s disease: clinical evidence and possible mechanism of neurogenesis. Biochem Pharmacol 2017;141:143–55. https://doi.org/10.1016/j.bcp.2017.07.002.
[21] Breithman II, Dardymov IV. New substances of plant origin which increase attention in patients with Alzheimer’s disease: a systematic review and meta-analysis. Curr Med Chem 2017;24:36. https://doi.org/10.2174/09298673247016032222.
[22] Nah SY. Ginseng ginsenoside nervous system in the nervous system: involvement in the regulation of ion channels and receptors. Front Physiol 2014;5:98. https://doi.org/10.3389/fphys.2014.00098.
[23] Nah SY, Kim DH, Rhim H. Ginsenosides: are any of them candidates for drugs acting on the central nervous system? CNS Drug Rev 2007;13:381–404. https://doi.org/10.1111/j.1527-3458.2007.00023.x.
[24] Dai D, Zhang CF, Williams S, Yuan CS, Wang CL. Ginseng on cancer: potential role in modulating inflammation-mediated angiogenesis. Am J Chin Med 2017;45(1):13–22. https://doi.org/10.11142/ajcm.2017.050021.
[25] Jiao R, Liu Y, Gao H, Xiao J, So RF. The anti-oxidant and antitumor properties of plant polysaccharides. Am J Chin Med 2016;44(3):463–88. https://doi.org/10.1142/s0129034416500269.
[26] Lee CH, Kim JH. A review on the medicinal potentials of ginseng and ginsenosides on cardiovascular diseases. J Ginseng Res 2014;38(3):161–6. https://doi.org/10.1016/j.jgr.2014.03.001.
Kim J, Kim SH, Lee DS, Lee DJ, Kim SH, Chung S, Yang HO. 

Sheng C, Peng W, Xia ZA, Wang Y, Chen Z, Su N, Wang Z. The impact of ginsenoside Rb1 on cognitive function in Alzheimer's disease: a systematic review. BMC Complement Altern Med 2015;15:386. https://doi.org/10.1186/s12906-015-0894-y.

Pyo MK, Choi SH, Hwang SH, Shin TJ, Lee BH, Lee SM, Yim KY, Kim DH, Nah SY. Ginsenoside Rb1 exerts a protective effect against Aβ42 and Aβ40 oligomer-induced toxicity in C121 cells. J Neurosci Res 2016;94:2802–22. https://doi.org/10.1002/jnr.23715.

Lee BH, Choi SH, Kim HJ, Jung SW, Kim KH, Nah SY. Plant lysosphaticidic acid-rich: a rich source for bioactive lysosphaticidic acids and their pharmacological applications. Biol Pharm Bull 2016;39:156–62. https://doi.org/10.1248/bpb.b15-00575.

Shi Y, Shi L, Jia Y, Zhang J, Wang Y, Sun Y. Ginsenoside Rg3 reduces aluminum-induced Aβ deposition in the brain of Tg-APPswe/PS1dE9 mouse model of Alzheimer disease experimental models. J Ginseng Res 2013;37:100–7. https://doi.org/10.5142/jgr.2013.37.100.

Lee ST, Chu K, Sim JY, Heo JH, Kim M. Panax ginseng enhances cognitive performance in Alzheimer disease. Alzheimers Dis Assoc Disord 2008;22:222–6. https://doi.org/10.1097/WAD.0b013e31816192e6.

Heo JH, Park MH, Lee JH. Effect of Korean red ginseng on cognitive function and cognitive impairment in patients with Alzheimer's disease: a preliminary study. J Altern Complement Med 2016;22:280–5. https://doi.org/10.1089/acm.2015.0265.

Habib A, Sawmiller D, Tan J. Restoring soluble amyloid precursor protein z functions as a potential treatment for Alzheimer's disease. J Neurosci Res 2017;95:973–91. https://doi.org/10.1002/jnr.23823.

Choi RJ, Roy A, Jung HJ, Ali MY, Min BS, Park CH, Yokozawa T, Fan TP, Choi JS, Jung HA. BACE1 molecular docking and anti-Alzheimer activity of ginsenoside Rd. J Ginseng Res 2018;42:401–8. https://doi.org/10.5142/jgr.2017.42.4.401.

Karpagam V, Sathishkumar N, Sathiyamoorthy S, Rasappan P, Shila S, Kim YJ, Qiu J, Li M, Han SY. Effects of ginsenoside Rg1 on cognitive function in Alzheimer's disease - a review. Biomed Life Sci 2017;182:286–297. https://doi.org/10.1007/978-3-319-44751-3_5.

Sun L, Wang Y, Zhao Q, Zhang X, Lou Y. Ginsenoside Rg1 exerts a protective effect against Aβ25-35-induced toxicity in primary cultured rat cortical neurones through up-regulation of choline acetyltransferase expression and neuroprotection. Regul Toxicol Pharmacol 2016;78:83–9. https://doi.org/10.1016/j.yrtph.2016.04.008.

Shin K, Shi Y, Lee BE, Choi SH, Jung SW, Cho H, Hwang SH, Kim KY, Han JS, Chung C, et al. Oral administration of gintonin attenuates cholinergic impairment by scopolamine, amyloid-β protein, and mouse model of Alzheimer's disease. Mol Cells 2015;39:786–95. https://doi.org/10.14348/molcells.2015.0116.
Qiao C, Den R, Kudo K, Yamada K, Takemoto K, Wati H, Kanba S. Ginseng enhances contextual fear conditioning and neurogenesis in rats. Neurosci Res 2005;51:31-8. https://doi.org/10.1016/j.neures.2004.09.004.

Sun GG, Shih JH, Chiou SH, Hong CJ, Lu SW, Pao LH. Chinese herbal medicines promote hippocampal neuroproliferation, reduce stress hormone levels, inhibit apoptosis, and improve behavior in chronically stressed mice. J Ethnopharmacol 2016;193:159-68. https://doi.org/10.1016/j.jep.2016.07.025.

Kim HJ, Kim DJ, Shin EJ, Lee BH, Choi SH, Hwang SH, Rhim H, Cho IH, Kim HC, Nah SY. Effects of gintonin-enriched fraction on hippocampal cell proliferation in wild-type mice and an APPswe/PSEN-1 double Tg mouse model of Alzheimer’s disease. Neurochem Int 2016;101:56-65. https://doi.org/10.1016/j.neuint.2016.10.006.

Kim HJ, Park SD, Lee RM, Lee BH, Choi SH, Hwang SH, Rhim H, Kim HC, Nah SY. Gintonin attenuates depressive-like behaviors associated with alcohol withdrawal in mice. J Affect Disord 2017;215:23-9.

Kim S, Kim MS, Park K, Kim HJ, Jung SW, Nah SY, Han JS, Chung C. Hippocampus-dependent cognitive enhancement induced by systemic gintonin administration. J Ginseng Res 2016;40:55-61. https://doi.org/10.1016/j.jgr.2015.05.001.

Moon J, Choi SH, Shim JY, Park HJ, Oh MJ, Kim M, Nah SY. Gintonin administration is safe and potentially beneficial in cognitively impaired elderly. Alzheimer Dis Assoc Disord 2017;Oct 12. https://doi.org/10.1097/WAD.0000000000000213 [ahead of print].

Schmitt FA, Cragar D, Ashford JW, Reisberg B, Ferris S, Möbius HJ, Stöfler A. Measuring cognition in advanced Alzheimer’s disease for clinical trials. J Neural Transm Suppl 2002;62:135-48.

Bodick NC, Offen WW, Shannon HE. Satterwhite J, Lucas R, van Lier R, Paul SM. The selective muscarinic agonist xanomeline improves both the cognitive deficits and behavioral symptoms of Alzheimer disease. Alzheimer Dis Assoc Disord 1997;11(Suppl. 4):S16-22.

Schmitt B, Bernhardt T, Moeller HJ, Heuser I, Frölich L. Combination therapy in Alzheimer’s disease: a review of current evidence. CNS Drugs 2004;18(13):827-44.

Patel L, Grossberg GT. Combination therapy for Alzheimer’s disease. Drugs Aging 2011;28(7):539-46. https://doi.org/10.2165/11591860-000000000-00000.